Form 4: Pacira BioSciences Director Equity Grant
Statement of Changes in Beneficial Ownership
Director Marcelo Bigal received a grant of 6,405 restricted stock units and 10,891 stock options.
Summary
- Director Marcelo Bigal was granted 6,405 restricted stock units (RSUs) on June 10, 2026.
- Director Marcelo Bigal was granted 10,891 stock options with an exercise price of $23.42 on June 10, 2026.
- Both the RSUs and stock options are subject to a one-year vesting period, becoming exercisable on June 10, 2027.
- Following these transactions, the director's total direct beneficial ownership of common stock is 17,798 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
- Retention of key board leadership through standard vesting schedules.
Negatives
- Potential for future shareholder dilution upon the exercise of stock options and vesting of RSUs.
Risks
- Continued service requirement for vesting creates a dependency on the director's ongoing tenure.
- Market price volatility could impact the future value of the granted equity.
Future Outlook
The equity grants are contingent upon the director remaining in continuous service with the issuer through June 10, 2027.
Industry Context
StockSavvy.ai notes that equity grants to board members are standard corporate governance practices designed to incentivize long-term oversight and alignment with shareholder interests in the biotechnology sector.
Comparison to Industry Standards
- The use of time-based vesting for director equity is consistent with standard practices for mid-cap biotechnology companies.
- The grant size is typical for non-employee director compensation packages in the pharmaceutical industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation | Grant of RSUs and stock options to Director Marcelo Bigal. | 06/10/2026 | Standard alignment of director incentives. |
Stakeholder Impact
- Shareholders may experience minor dilution upon future exercise of options.
Next Steps
- Vesting of equity grants on June 10, 2027.
Key Dates
| Date | Description |
|---|---|
| 06/10/2026 | Date of equity grant transaction. |
| 06/10/2027 | Vesting date for RSUs and stock options. |
| 06/10/2036 | Expiration date for stock options. |
| 06/12/2026 | Filing date of the Form 4. |
Keywords
Pacira BioSciences, PCRX, Form 4, Insider Trading, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.